SafiBio Revenue and Competitors
Estimated Revenue & Valuation
- SafiBio's estimated annual revenue is currently $2M per year.
- SafiBio's estimated revenue per employee is $155,000
Employee Data
- SafiBio has 13 Employees.
- SafiBio grew their employee count by 8% last year.
SafiBio's People
Name | Title | Email/Phone |
---|
SafiBio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is SafiBio?
Delivering innovative and effective BioTech solutions! SafiBio is based in the United States and Côte d'Ivoire. We operate across several sectors that affect populations daily. SafiBio offers innovative, healthy, efficient, economical, and sustainable applied biotech solutions. Our main sectors of activities are agriculture, agri-food, health, and wellness. Our solutions are comprehensives and span the entire value chain. As a company and under the impulsion of our leadership we envision the application of biotechnology and other new technologies to serve and support the agricultural, health and wellness industries in Africa; by researching, developing, innovating, and streamlining the supply of top quality, natural, safe, and effective life improving and healing products for Humans, Animals and Plants.
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 13 | 0% | N/A |
#2 | $2.1M | 13 | N/A | N/A |
#3 | $1.9M | 13 | -7% | N/A |
#4 | $1.4M | 13 | -19% | N/A |
#5 | $1.6M | 13 | -24% | N/A |